Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 1:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 714 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Vincristine Clear all
Terminated Phase 2 Interventional Results available

Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)

NCT01925612
View directory record Official record
Conditions
Lymphoma, B-cell, Lymphoma, Large B-cell, Diffuse
Interventions
brentuximab vedotin, rituximab, vincristine, cyclophosphamide, prednisone, doxorubicin
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
36
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2018 · Synced Oct 17, 2026, 1:04 AM EDT
Completed Phase 2 Interventional

Liposomal Vincristine for Pediatric and Adolescent Patients With Relapsed Malignancies

NCT00038207
View directory record Official record
Conditions
Soft Tissue Sarcoma, Lymphoma, Leukemia, Wilms' Tumor, Osteosarcoma
Interventions
Liposomal Vincristine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Oct 17, 2026, 1:04 AM EDT
Active, not recruiting Phase 1 Interventional

Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia

NCT05157971
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, Ph-Like Acute Lymphoblastic Leukemia
Interventions
Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Venetoclax, Vincristine Sulfate
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 54 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 17, 2026, 1:04 AM EDT
Completed Phase 2 Interventional Results available

A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma

NCT00337987
View directory record Official record
Conditions
Peripheral T-Cell Lymphoma
Interventions
Ontak, CHOP (cyclophosphamide (C), adriamycin (H), vincristine (O), and prednisone (P)) chemotherapy
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 27, 2015 · Synced Oct 17, 2026, 1:04 AM EDT
Terminated Phase 2 Interventional Results available

Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia

NCT00882206
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
cytarabine, decitabine, doxorubicin hydrochloride, imatinib mesylate, methotrexate, pegaspargase, prednisone, vincristine sulfate, vorinostat
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
2 Years to 60 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 17, 2026, 1:04 AM EDT
Completed Not applicable Interventional

Managing Medication-induced Constipation in Cancer: A Clinical Trial

NCT01416909
View directory record Official record
Conditions
Constipation
Interventions
Laxative Treatment, Standard of Care, Assessment Questionnaires
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 17, 2026, 1:04 AM EDT
Recruiting Phase 2 Interventional

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

NCT04803201
View directory record Official record
Conditions
Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Follicular T-Cell Lymphoma, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Peripheral T-Cell Lymphoma, Not Otherwise Specified
Interventions
Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Etoposide, Duvelisib, Oral azacitidine
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
96
States / cities
Little Rock, Arkansas • Duarte, California • La Jolla, California + 74 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 17, 2026, 1:04 AM EDT
Completed Phase 1 Interventional

A Pilot Study for the Treatment of Patients With Metastatic and High Risk Sarcomas and Primitive Neuroectodermal Tumors

NCT00001209
View directory record Official record
Conditions
Neuroectodermal Tumor, Primitive, Neuroepithelioma, Osteosarcoma, Sarcoma, Sarcoma, Ewing's
Interventions
vincristine, adriamycin and cytoxan, alternating with ifosfamide VP-16
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1986 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 17, 2026, 1:04 AM EDT
Completed Not applicable Interventional Results available

High-Risk Neuroblastoma Chemotherapy Without G-CSF

NCT02786719
View directory record Official record
Conditions
Neuroblastoma
Interventions
Topotecan, Cyclophosphamide, Cisplatin, Etoposide, Vincristine, Doxorubicin, Sargramostim
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
12 Months to 18 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
San Diego, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Oct 17, 2026, 1:04 AM EDT
Terminated Phase 2Phase 3 Interventional

Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body

NCT06820957
View directory record Official record
Conditions
CIC-Rearranged Sarcoma, Metastatic Ewing Sarcoma, Metastatic High Grade Sarcoma, Metastatic Undifferentiated Round Cell Sarcoma, Metastatic Undifferentiated Sarcoma, Not Otherwise Specified, Round Cell Sarcoma With EWSR1-non-ETS Fusion, Sarcoma With BCOR Genetic Alterations
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Echocardiography Test, Etoposide, Fludeoxyglucose F-18, Ifosfamide, Irinotecan Hydrochloride, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Radiation Therapy, Regorafenib, Surgical Procedure, Vincristine Sulfate
Procedure · Drug · Other + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
12 Years to 50 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
8
States / cities
Birmingham, Alabama • Honolulu, Hawaii • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 17, 2026, 1:04 AM EDT
Completed Phase 2 Interventional Results available

Doxorubicin (Doxil) Combined With Rituxan, Cyclophosphamide, Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas

NCT00184002
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
Doxorubicin, Rituxan, Cyclophosphamide, Vincristine and Prednisone
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Oct 17, 2026, 1:04 AM EDT
Completed Phase 2 Interventional Results available

Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

NCT00301821
View directory record Official record
Conditions
Lymphoma
Interventions
epratuzumab, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
162
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 102 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Oct 17, 2026, 1:04 AM EDT
Active, not recruiting Not applicable Interventional

International Pleuropulmonary Blastoma (PPB) Treatment and Biology Registry

NCT01464606
View directory record Official record
Conditions
Pleuropulmonary Blastoma
Interventions
Vincristine, Dactinomycin, Cyclophosphamide, Ifosfamide, Doxorubicin
Drug
Lead sponsor
Children's Hospitals and Clinics of Minnesota
Other
Eligibility
Up to 21 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Oct 17, 2026, 1:04 AM EDT
Terminated Phase 2 Interventional

S0349 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Treating Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's Lymphoma

NCT00080847
View directory record Official record
Conditions
Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma
Interventions
oblimersen sodium, rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years to 59 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced Oct 17, 2026, 1:04 AM EDT
Recruiting Phase 2 Interventional

Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

NCT00501826
View directory record Official record
Conditions
T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma
Interventions
Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Mercaptopurine, Methotrexate, Nelarabine, Pegaspargase, Prednisone, Venetoclax, Vincristine Sulfate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 17, 2026, 1:04 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor

NCT00002643
View directory record Official record
Conditions
Neutropenia, Sarcoma
Interventions
filgrastim, amifostine trihydrate, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, topotecan hydrochloride, vincristine sulfate, conventional surgery, low-LET cobalt-60 gamma ray therapy, low-LET electron therapy, low-LET photon therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 30 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
43
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2013 · Synced Oct 17, 2026, 1:04 AM EDT
Completed Phase 1 Interventional

T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies

NCT00080925
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
filgrastim, graft-versus-tumor induction therapy, rituximab, therapeutic allogeneic lymphocytes, cyclophosphamide, cyclosporine, cytarabine, doxorubicin hydrochloride, etoposide, fludarabine phosphate, prednisone, vincristine sulfate, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 8, 2012 · Synced Oct 17, 2026, 1:04 AM EDT
Completed Phase 2 Interventional Results available

Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma

NCT01118026
View directory record Official record
Conditions
Lymphoma
Interventions
ABVD, BEACOPP, radiation therapy
Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 60 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
55
States / cities
San Diego, California • St. Helena, California • Lewes, Delaware + 44 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2021 · Synced Oct 17, 2026, 1:04 AM EDT
Completed Phase 2 Interventional Results available

Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors

NCT00365768
View directory record Official record
Conditions
Kidney Cancer, Leukemia, Lymphoma, Neurotoxicity, Peripheral Neuropathy, Sarcoma
Interventions
Glutamine, Placebo
Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
5 Years to 21 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 9, 2016 · Synced Oct 17, 2026, 1:04 AM EDT
Completed Phase 1 Interventional

Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

NCT00070083
View directory record Official record
Conditions
Lymphoma
Interventions
oblimersen sodium, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate
Biological · Drug
Lead sponsor
British Columbia Cancer Agency
Other
Eligibility
19 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2009 · Synced Oct 17, 2026, 1:04 AM EDT
Completed Phase 2 Interventional Results available

Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma

NCT00058422
View directory record Official record
Conditions
Lymphoma
Interventions
darbepoetin alfa, filgrastim, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, indium In 111 ibritumomab tiuxetan, yttrium Y 90 ibritumomab tiuxetan
Biological · Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
60 Years to 120 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2019
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Oct 17, 2026, 1:04 AM EDT
Completed Phase 2 Interventional Results available

Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma

NCT00669877
View directory record Official record
Conditions
Burkitt's Lymphoma, Burkitt'S-like Lymphoma
Interventions
Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Dexamethasone, G-CSF, Cytarabine, Methotrexate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Oct 17, 2026, 1:04 AM EDT
Active, not recruiting Phase 3 Interventional

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

NCT04759586
View directory record Official record
Conditions
Primary Mediastinal Large B-Cell Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Echocardiography Test, Etoposide Phosphate, Filgrastim, Lumbar Puncture, Nivolumab, Pegfilgrastim, Positron Emission Tomography, Prednisolone, Prednisone, Radiation Therapy, Rituximab, Rituximab and Hyaluronidase Human, Vincristine Sulfate
Procedure · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
215
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 162 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 17, 2026, 1:04 AM EDT
Withdrawn Phase 2 Interventional

Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)

NCT02605694
View directory record Official record
Conditions
Lymphoma
Interventions
Duvelisib, Rituximab, R-CHOP, Prednisone
Drug
Lead sponsor
SecuraBio
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Oct 17, 2026, 1:04 AM EDT